The California Institute for Regenerative Medicine (CIRM) is exploring options for its future as funding provided through its bond issue dwindles. In a meeting earlier this week, two governing board committees of the agency focused on short and long term finances including a proposal to cut clinical awards by $68 million over the next two years, an effort to raise $222 million in private funding, and the possibility of a $5 billion ballot initiative in November 2020, according to the California Stem Cell Report.